Background: Treatment guidelines and US Food and Drug Administration emergency use
authorizations (EUAs) of monoclonal antibodies (mAbs) for treatment of high-risk outpatients …

Objective: Previous experiments in the authors swine lab have shown that cardiopulmonary
resuscitation (CPR) using two‐thumb chest compression with a thoracic squeeze (TT) …

Background Monoclonal antibody treatment may prevent complications of coronavirus
disease 2019 (COVID-19). We sought to quantify the impact of bamlanivimab monoclonal …

Importance The effectiveness of monoclonal antibodies (mAbs), casirivimab-imdevimab and
sotrovimab, is unknown in patients with mild to moderate COVID-19 caused by the SARS-…

Importance Monoclonal antibody (mAb) treatment decreases hospitalization and death in
high-risk outpatients with mild to moderate COVID-19; however, only intravenous …

Introduction About one-third of critically ill patients with acute kidney injury (AKI) develop
persistently decreased kidney function, known as acute kidney disease (AKD), which may …

Importance The 23rd Acute Disease Quality Initiative (ADQI-23) consensus conference
proposed a framework to integrate biomarkers into the staging of acute kidney injury (AKI). It is …

Background Monoclonal antibody (mAb) treatment is associated with decreased risk of
hospitalization and death in high-risk outpatients with mild to moderate coronavirus disease 2019 …

Objectives The primary objective is to evaluate the comparative effectiveness of COVID-19
specific monoclonal antibodies (mABs) with US Food and Drug Administration (FDA) …

Emergency authorized coronavirus disease 2019 (COVID-19)–neutralizing monoclonal
antibodies can aid outpatients with mild to moderate COVID-19 infection. Many report barriers to …